Literature DB >> 10671769

Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms.

M Voutilainen1, P Sipponen, J P Mecklin, M Juhola, M Färkkilä.   

Abstract

BACKGROUND AND AIMS: Gastroesophageal reflux disease (GERD) reportedly has increased in prevalence while Helicobacter pylori infection and peptic ulcer disease have been on the decrease. The aim of the present study was to examine the prevalence of GERD as well as the clinical, endoscopic and histologic variables that associate with GERD in patients referred for endoscopy. PATIENTS AND METHODS: The study population was drawn from 1,562 consecutive patients referred for endoscopy. The exclusion criteria were previous H. pylori eradication, gastric surgery, anemia and weight loss. Thus 1,128 patients were enrolled in the present study.
RESULTS: Of the 1,128 patients, 199 (18%) were referred for endoscopy due to heartburn and/or regurgitation. GERD, defined as chronic (>6 months) heartburn and/or regurgitation with or without erosive esophagitis, Barrett's esophagus, esophageal ulcer or stricture, was detected in 248 (22%) patients. Of the 248 GERD patients, 81 (33%) had endoscopy-negative GERD, but of those aged <50 years (n = 67), 57 (85%) were endoscopy-negative. The overall incidence of GERD was 307 per 100,000 population/year and that of endoscopy-positive GERD 207/100,000/year. The positive and negative predictive values of heartburn and regurgitation for endoscopy-positive GERD were 0.37 (95% CI 0.31-0.44) and 0.90 (95% CI 0.88-0.92), respectively. Independent risk factors for GERD were male sex (OR 1.9, 95% CI 1.3-2.7), previous medication for upper gastrointestinal symptoms (OR 2.7, 95% CI 1.7-4.1), the use of nonsteroidal anti-inflammatory drugs (NSAIDs; OR 2.0, 95% CI 1.3-3. 0), histologic esophagitis (OR 2.2, 95% CI 1.5-3.2) and incomplete intestinal metaplasia at the gastroesophageal junction (OR 1.7, 95% CI 1.0-3.1). Chronic gastritis was protective against GERD (OR 0.7, 95% CI 0.5-0.9). No association was observed between GERD and H. pylori infection. The risk of patients aged <50 years (n = 407) of having major lesion (Barrett's esophagus, esophageal stricture, peptic ulcer, esophageal/gastric carcinoma) was significantly lower than that of patients aged >50 years (n = 721; OR 0.5, 95% CI 0.3-0. 9, p = 0.01).
CONCLUSIONS: The correlation between reflux symptoms and endoscopy-positive GERD is poor and most GERD patients aged <50 years have endoscopy-negative GERD. The use of NSAIDs is a risk factor for GERD, whereas chronic gastritis, but not H. pylori infection, may protect against GERD. Incomplete intestinal metaplasia at the gastroesophageal junction is associated with GERD. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2000        PMID: 10671769     DOI: 10.1159/000007730

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  33 in total

Review 1.  New approaches to Helicobacter pylori infection in children.

Authors:  B D Gold
Journal:  Curr Gastroenterol Rep       Date:  2001-06

Review 2.  Inflammation in the cardia.

Authors:  M Voutilainen; P Sipponen
Journal:  Curr Gastroenterol Rep       Date:  2001-06

3.  The prevalence of Barrett's esophagus and erosive esophagitis in patients undergoing upper endoscopy for dyspepsia in a VA population.

Authors:  Michael J Connor; Allan P Weston; Matthew S Mayo; Prateek Sharma
Journal:  Dig Dis Sci       Date:  2004-06       Impact factor: 3.199

4.  Population based study to assess prevalence and risk factors of gastroesophageal reflux disease in a high altitude area.

Authors:  Sushil Kumar; Saurabh Sharma; Tsering Norboo; Diskit Dolma; Angchuk Norboo; Tsering Stobdan; S Rohatgi; K Munot; Vineet Ahuja; Anoop Saraya
Journal:  Indian J Gastroenterol       Date:  2010-12-23

5.  Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease.

Authors:  K Størdal; G B Johannesdottir; B S Bentsen; P K Knudsen; K C L Carlsen; O Closs; M Handeland; H K Holm; L Sandvik
Journal:  Arch Dis Child       Date:  2005-09       Impact factor: 3.791

Review 6.  Barrett's esophagus--Who, how, how often and what to do with dysplasia?

Authors:  Lawrence C Hookey
Journal:  Can J Gastroenterol       Date:  2006-07       Impact factor: 3.522

Review 7.  Barrett esophagus: what a mouse model can teach us about human disease.

Authors:  Michael Quante; Julian A Abrams; Yoomi Lee; Timothy C Wang
Journal:  Cell Cycle       Date:  2012-10-24       Impact factor: 4.534

8.  Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men.

Authors:  Jennifer R Kramer; Lori A Fischbach; Peter Richardson; Abeer Alsarraj; Stephanie Fitzgerald; Yasser Shaib; Neena S Abraham; Maria Velez; Rhonda Cole; Bhupinderjit Anand; Gordana Verstovsek; Massimo Rugge; Paola Parente; David Y Graham; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-12-04       Impact factor: 11.382

9.  Gastric acid normosecretion is not essential in the pathogenesis of mild erosive gastroesophageal reflux disease in relation to Helicobacter pylori status.

Authors:  Tomohiko Shimatani; Masaki Inoue; Nobue Harada; Yoko Horikawa; Masuo Nakamura; Susumu Tazuma
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

Review 10.  Reflux esophagitis, high-grade neoplasia, and early Barrett's carcinoma-what is the place of the Merendino procedure?

Authors:  A H Hölscher; D Vallböhmer; C Gutschow; E Bollschweiler
Journal:  Langenbecks Arch Surg       Date:  2008-11-07       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.